Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The price of Taysha Gene Therapies Inc (NASDAQ: TSHA) closed at $2.71 in the last session, up 3.04% from day before closing price of $2.63. In other words, the price has increased by $3.04 from its previous closing price. On the day, 2.31 million shares were traded. TSHA stock price reached its highest trading level at $2.75 during the session, while it also had its lowest trading level at $2.54.
Ratios:
We take a closer look at TSHA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.35 and its Current Ratio is at 5.35. In the meantime, Its Debt-to-Equity ratio is 1.13 whereas as Long-Term Debt/Eq ratio is at 1.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on July 11, 2025, initiated with a Buy rating and assigned the stock a target price of $8.
On June 27, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $5.
On April 09, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $9.Piper Sandler initiated its Overweight rating on April 09, 2024, with a $9 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 30 ’25 when Manning Paul B bought 750,000 shares for $2.75 per share. The transaction valued at 2,062,500 led to the insider holds 2,841,704 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TSHA now has a Market Capitalization of 708746304 and an Enterprise Value of 526769248. For the stock, the TTM Price-to-Sale (P/S) ratio is 98.16 while its Price-to-Book (P/B) ratio in mrq is 10.09. Its current Enterprise Value per Revenue stands at 72.919 whereas that against EBITDA is -6.384.
Stock Price History:
The Beta on a monthly basis for TSHA is 0.97, which has changed by 0.26046515 over the last 52 weeks, in comparison to a change of 0.20799685 over the same period for the S&P500. Over the past 52 weeks, TSHA has reached a high of $3.31, while it has fallen to a 52-week low of $1.05. The 50-Day Moving Average of the stock is 4.44%, while the 200-Day Moving Average is calculated to be 32.36%.
Shares Statistics:
According to the various share statistics, TSHA traded on average about 3.83M shares per day over the past 3-months and 2622500 shares per day over the past 10 days. A total of 261.53M shares are outstanding, with a floating share count of 223.79M. Insiders hold about 14.43% of the company’s shares, while institutions hold 66.42% stake in the company. Shares short for TSHA as of 1752537600 were 43962246 with a Short Ratio of 11.48, compared to 1749772800 on 33272908. Therefore, it implies a Short% of Shares Outstanding of 43962246 and a Short% of Float of 18.879999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
At present, 4.0 analysts are actively evaluating the performance of Taysha Gene Therapies Inc (TSHA) in the stock market.The consensus estimate for the next quarter is -$0.08, with high estimates of -$0.06 and low estimates of -$0.09.
Analysts are recommending an EPS of between -$0.24 and -$0.34 for the fiscal current year, implying an average EPS of -$0.3. EPS for the following year is -$0.36, with 5.0 analysts recommending between -$0.24 and -$0.55.
Revenue Estimates
A total of 12 analysts have provided revenue estimates for TSHA’s current fiscal year. The highest revenue estimate was $15M, while the lowest revenue estimate was $2.3M, resulting in an average revenue estimate of $7.14M. In the same quarter a year ago, actual revenue was $8.33M
